www.brimstalt.com
The startup develops small molecule prodrugs that activate into cytotoxic agents through the overexpression of specific intracellular enzymes in cancer cells. This approach targets common cancers with significant patient populations and high unmet medical needs, providing selective therapy options for patients with limited treatment alternatives.
Traction –/10
HQ unknown
- Biotechnology
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops small molecule prodrugs that activate into cytotoxic agents through the overexpression of specific intracellular enzymes in cancer cells. This approach targets common cancers with significant patient populations and high unmet medical needs, providing selective therapy options for patients with limited treatment alternatives.